[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bristol-Myers Squibb\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":662},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,115,0,25,[9,46,77,106,143,164,185,203,228,255,281,304,329,354,380,401,421,447,476,498,522,562,593,611,641],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100601935","phase-3-long-term-safety-study-of-deucravacitinib-versus-ustekinumab-in-participants-with-psoriasis-pragmatyk-100601935",false,"NCT07116967","Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)","A Phase 3b\u002F4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Participants with moderate-to-severe plaque psoriasis:\n\n  1. Deemed by the Investigator to be a candidate for phototherapy or systemic treatment for psoriasis, including ustekinumab;\n  2. Have at least 1 of the following cardiovascular risk factors:\n* Current cigarette smoker\n* Diagnosis of hypertension\n* Diagnosis of hyperlipidemia\n* Diabetes mellitus type 1 or 2\n* History of one or more of the following cardiovascular events: Coronary intervention (PCI) or coronary artery bypass grafting (CABG), myocardial infarction (heart attack), cardiac arrest, hospitalization for unstable angina, acute coronary syndrome, stroke, or transient ischemic attack\n* Obesity\n* Family history of premature coronary heart disease or sudden death in a first-degree male relative younger than 55 years of age or in a first-degree female relative younger than 65 years of age.\n\nExclusion Criteria:\n\n* Participants must not have recent history of 1 of the following cardiovascular events: MI, stroke, or coronary revascularization, or VTE within 90 days prior to Day 1.\n* Participants must not have unstable CVD, defined as a recent clinical cardiovascular event (eg, unstable angina, rapid atrial fibrillation), or a cardiac hospitalization (eg, pacemaker implantation, HF) within 90 days prior to Day 1.\n* Participants must not have evidence of active cancer or history of cancer (solid organ or hematologic malignancy including myelodysplastic syndrome) or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma, or carcinoma of cervix in situ that has been treated with no evidence of recurrence).\n* Other protocol define inclusion\u002Fexclusion criteria apply.","ALL","40 Years",{"count":20,"type":21},3040,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis",[27],"Plaque Psoriasis",[29,30,31,32],"Deucravacitinib","Plaque psoriasis","Cardiovascular risk","PRAGMATYK","RECRUITING","2026-08-20",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":37},"2025-09-22",{"date":41,"type":21},"2031-01-16",{"name":43,"class":44},"Bristol-Myers Squibb","INDUSTRY",402,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100652901","phase-1-a-study-to-evaluate-the-drug-levels-absolute-bioavailability-safety-tolerability-and-immunogenicity-of-single-dose-of-bms-986446-in-healthy-adults-after-single-dose-administration-and-participants-with-early-alzheimers-disease-after-multiple-dose-administration-100652901","NCT07780383","A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration","A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.","Inclusion Criteria\n\n* Participants must have a BMI of 18.0 to 35.0 kg\u002Fm2.\n* For Parts A and B: Participants must be healthy as determined by medical history, Physical Examination (PE), neurological examination, vital signs, 12-lead ECG, Columbia Suicide-Severity Rating Scale (C-SSRS), and clinical laboratory evaluations.\n* For Part C: Participants must meet diagnostic criteria for MCI or mild AD dementia, consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) diagnostic criteria.\n* For Part C: Participants must have an Mini Mental State Examination (MMSE) score of ≥ 20 to 28 (inclusive).\n* For Part C: Participants must have evidence of positive plasma pTau217.\n\nExclusion Criteria\n\n* For Parts A and B: Participants must not have a general history of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.\n* For Parts A and B: Participants must not have donated or lost 500 mL blood or more within 60 days prior to study intervention administration.\n* For Part C: Participants must not have a neurological condition that in the opinion of the investigator may be contributing to cognitive impairment aside from the AD diagnosis, including but not limited to: Parkinson's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, long COVID, or baseline intellectual disability.\n* For Part C: Participants must not have any current primary psychiatric diagnosis (eg, major depression, schizoaffective disorder or bipolar disorder) other than AD or symptoms (eg, hallucination or delusions).\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"18 Years","80 Years",{"count":57,"type":21},84,[59],"PHASE1","The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration",[62,63],"Alzheimer's Disease","Healthy Participants",[63,65,66,67,68],"Early Alzheimer's Disease","BMS-986446","Subcutaneous Administration","IV administration","NOT_YET_RECRUITING","2026-08-19",{"date":36,"type":37},{"date":36,"type":21},{"date":74,"type":21},"2027-06-17",{"name":43,"class":44},1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100591114","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-karxt--karx-ec-for-cognitive-impairment-in-alzheimers-disease-100591114","NCT06976216","A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 1)","MINDSET 1","Inclusion Criteria\n\n* Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach.\n* Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening.\n* Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits. The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities.\n* Participants on acetyl choline esterase inhibitors (AChEIs) and\u002For memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration.\n\nExclusion Criteria\n\n* Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment, urinary retention, active biliary disease, moderate-severe renal impairment (eGFR of \\\u003C50 mL\u002Fmin), and unstable hypertension or tachycardia.\n* Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion.\n* Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening.\n* Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that reflect significant pathology other than AD or could affect safety or interfere with study procedures.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","60 Years","85 Years",{"count":88,"type":21},586,[24],"The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease",[62],[93,94,95,96,97,98],"Dementia","Cognitive Impairment","Kar-XT","KarX-EC","Mild Alzheimer's Disease","Moderate Alzheimer's Disease",{"date":34,"type":37},{"date":101,"type":37},"2025-07-14",{"date":103,"type":21},"2029-02-23",{"name":43,"class":44},119,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":53,"sex":113,"minAge":54,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100652630","phase-1-a-study-to-evaluate-the-metabolism-the-routes-and-extent-of-elimination-and-drug-levels-of-14cnavlimetostat-bms-986504-in-healthy-female-participants-100652630","NCT07777133","A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants","A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]Navlimetostat (BMS-986504) at Steady State in Healthy Female Participants","Inclusion Criteria\n\n* Participants must have a body mass index (BMI) of 18.0 to 35.0 kg\u002Fm2, inclusive.\n* Participants must have a recent history (ie, last month) of a minimum of 1 bowel movement per 2 days.\n* Participants must be female (as assigned at birth) who is an individual not of childbearing potential (INOCBP), defined as one of the following:.\n\n  i) Surgically sterile (eg, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).\n\nii) Postmenopausal, defined as ≥ 12 consecutive months of amenorrhea in an individual over the age of 45 years (no other biological or physiological causes), and individuals \\\u003C 55 years of age with 12 months of amenorrhea must have serum FSH levels \\> 40 mIU\u002FmL at screening to confirm menopausal status.\n\nExclusion Criteria\n\n* Participants must not have any significant acute or chronic medical illness.\n* Participants must not have current or recent gastrointestinal disease.\n* Participants must not have a history of prolonged bleeding or excessive bruising.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","FEMALE","55 Years",{"count":116,"type":21},6,[59],"The purpose of this study is to evaluate the metabolism, the routes and extent of elimination, and drug levels of \\[14C\\]Navlimetostat (BMS-986504) in healthy female participants",[120],"Healthy Female Participants",[122,123,124,125,126,127,128,129,130,131,132,133,134],"Protein arginine methyltransferase (PRMT5)","Methylthioadenosine-cooperative PRMT5 inhibitor","Homozygous methylthioadenosine phosphorylase (MTAP) deletion","Mass balance study","Metabolism","Elimination","Drug absorption","Distribution","Excretion","Radiolabeled","Absorption","Excretion (ADME)","Navlimtostat","2026-08-18",{"date":34,"type":37},{"date":138,"type":21},"2026-09-16",{"date":140,"type":21},"2026-12-05",{"name":43,"class":44},2,{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},"100622146","effectiveness-and-adverse-effect-switch-evaluation-of-xanomeline-and-trospium-chloride-karxt-100622146","NCT07379827","Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)","Effectiveness and Adverse-effect Switch Evaluation","Inclusion Criteria:\n\n* Participants (or caregiver\u002Flegal guardian) must have signed and dated an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC)-approved written ICF or signed an electronic ICF in accordance with regulatory, local, and institutional guidelines.\n* Adults ≥ 18 years of age at Baseline who are willing and able, in the judgement of the treating clinician, to participate in routine clinical care and follow up.\n* Schizophrenia, confirmed by the treating clinician's judgement or physician decision to treat the patient with receiving xanomeline and trospium chloride (KarXT) for schizophrenia made prior to and independently of participation in this study. Current Antipsychotic Treatment: Participant must fall into one of the categories below:\n\n  * Be within \\\u003C16 weeks of initiating treatment with KarXT with intent to discontinue prior antipsychotic treatment(s) OR\n  * On a stable regimen (dose and frequency consistent with the drug label and\u002For at a stable dose based on the judgement of the Investigator for at least 30 days prior to screening) of treatment with 1 or more antipsychotics with plan to discontinue and switch to treatment with KarXT from a prior antipsychotic treatments(s). NOTE: The decision to switch for reasons of safety, tolerability, and\u002For efficacy will be made independently by the treating clinician and\u002For the patient and is not dictated by the study. Participants can be enrolled during tapering\u002Fdiscontinuing process from prior antipsychotic treatment(s). Individuals who are not currently receiving treatment for schizophrenia are not eligible for the study. Any antipsychotic treatments must be recorded as concomitant medications.\n* Concomitant psychiatric medications (eg, antidepressants, mood stabilizers, anxiolytics) are permitted and are recommended to remain at a stable dose during the study period.\n\nExclusion Criteria:\n\n* Prior use of KarXT that has been discontinued for any reason prior to Baseline.\n* Participation in an interventional study within the last 30 days or plans to participate in an interventional study at the time of eligibility or baseline through the study period.\n* Known hypersensitivity to xanomeline or trospium chloride, or history or high risk of urinary retention, gastric retention, moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment, or narrow-angle glaucoma.\n* In the opinion of the treating clinician, unstable psychiatric or medical conditions that would prevent the participant from safely switching to KarXT. Hospitalized individuals who have been switched to KarXT or are switching treatment to KarXT are permitted to be enrolled at discharge if they are \\\u003C 16 weeks from initiation of KarXT.\n* Participants who are pregnant, planning to become pregnant, or breastfeeding.",{"count":151,"type":21},1500,"OBSERVATIONAL","The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States",[155],"Schizophrenia",[155],{"date":70,"type":37},{"date":159,"type":37},"2026-02-26",{"date":161,"type":21},"2028-06-20",{"name":43,"class":44},55,{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100609545","a-real-world-study-to-evaluate-luspatercept-in-adults-with-transfusion-dependent-beta-thalassemia-in-the-middle-east-100609545","NCT07215975","A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East","REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE): A Non-interventional Retrospective and Prospective Observational Study","Inclusion Criteria:\n\n* Male or female participants of any race aged at least 18 years at time of initiation of luspatercept treatment\n* Participants with documented diagnosis of transfusion-dependent β-thalassemia (TDT).\n* Participants who have been initiated on treatment with luspatercept as per the product's Summary of Product Characteristics (SmPC) no longer than 12 months prior to informed consent signature, and for whom therapy is ongoing.\n* Participants for whom the decision to prescribe luspatercept treatment is clearly separated from the physician's decision to include the participant in the current study.\n* Participants who have provided signed informed consent for participating in the study and for collecting and analyzing medical data pertinent to the objectives of this study\n\nExclusion Criteria:\n\n* Participants that meet any of the contraindications to the administration of luspatercept as outlined in the latest version of the locally approved SmPC.\n* Participants who are currently receiving or are planned to receive treatment with any investigational drug\u002Fdevice\u002Fintervention or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to luspatercept therapy initiation.\n* Participants who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period.\n* Participants who have not provided signed informed consent for participating in the study and for collecting and analysing medical data pertinent to the objectives of this study.",{"count":172,"type":21},200,"The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East",[175],"β-thalassemia",[177],"Transfusion-dependent β-thalassemia",{"date":70,"type":37},{"date":180,"type":37},"2026-06-26",{"date":182,"type":21},"2031-04-17",{"name":43,"class":44},13,{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":201,"locationsCount":202},"100600715","evaluation-of-treatment-satisfaction-and-karxt-utilization-registry-resku-100600715","NCT07101094","Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)","Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)","Inclusion Criteria:\n\n* Aged ≥18 years at index date.\n* Have a confirmed diagnosis of schizophrenia before index date.\n* Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy.\n* Provide a signed and dated Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines.\n* Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish).\n* English or Spanish speaking.\n\nExclusion Criteria:\n\n* Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening.\n* Evidence of use of XT prior to time of eligibility screening.",{"count":193,"type":21},300,"The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X\u002FT) therapy",[155],[155],{"date":70,"type":37},{"date":39,"type":37},{"date":200,"type":21},"2029-05-14",{"name":43,"class":44},20,{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":17,"minAge":114,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":214,"conditions":215,"keywords":218,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},"100588118","phase-3-a-study-to-evaluate-the-long-term-efficacy-and-safety-of-karxt--karx-ec-for-agitation-in-alzheimers-disease-adagio-3-100588118","NCT06937229","A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)","A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)","Inclusion Criteria:\n\n* Participants must have completed study CN012-0023 or CN012-0024 per protocol.\n* Participants must have an identified caregiver who has sufficient contact (approximately 8 hours over a week).\n\nExclusion Criteria:\n\n* Participants must not have clinically significant cardiovascular (eg, untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","90 Years",{"count":212,"type":21},650,[24],"The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate\u002Ftrospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.",[216,217],"Alzheimer Disease","Agitation",[217,219,220,96],"Alzheimer disease","KarXT",{"date":70,"type":37},{"date":223,"type":37},"2025-12-02",{"date":225,"type":21},"2029-07-20",{"name":43,"class":44},256,{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":17,"minAge":235,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":254},"100582917","phase-3-a-study-to-evaluate-the-drug-levels-efficacy-and-safety-of-deucravacitinib-bms-986165-in-pediatric-participants-with-juvenile-psoriatic-arthritis-100582917","NCT06869551","A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis","A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis","Inclusion Criteria\n\n* Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).\n* Participants must have at least three joints that are affected by arthritis.\n* Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.\n\nExclusion Criteria\n\n* Participants must not have been diagnosed with JPsA before 5 years of age.\n* Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,\n* Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","5 Years","17 Years",{"count":238,"type":21},60,[24],"The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.",[242],"Juvenile Psoriatic Arthritis",[244,245,246,29,247],"Juvenile Psoriatic Arthritis (JPsA)","Juvenile Idiopathic Arthritis (JIA)","Pediatric PsA","BMS-986165",{"date":70,"type":37},{"date":250,"type":37},"2025-03-13",{"date":252,"type":21},"2031-03-04",{"name":43,"class":44},47,{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":263,"targetDuration":235,"studyType":152,"phases":4,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":280},"100476881","a-prospective-registry-study-to-assess-real-world-patient-characteristics-treatment-patterns-and-longitudinal-outcomes-in-patients-receiving-mavacamten-and-other-treatments-for-symptomatic-obstructive-hypertrophic-cardiomyopathy-obstructive-hcm-100476881","NCT05489705","A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)","Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States and European Prospective Registry Study","DISCOVER-HCM","Inclusion Criteria\n\n* ≥ 18 years of age at the time of informed consent.\n* Willing and able to provide written informed consent form (ICF) and any required privacy authorization prior to the initiation of study procedures (or in those situations where consent cannot be given by participants, consent provided by their legally acceptable representatives)\n\nUnited States Sub-Study\n\n* Diagnosis of obstructive HCM consistent with 2020 American Heart Association\u002FAmerican College of Cardiology (AHA\u002FACC) guidelines.\n\n  * Obstructive HCM is defined clinically by the presence of increased LV wall thickness ≥ 15 mm (or ≥ 13 mm with positive family history of HCM) in a nondilated ventricular chamber that is not solely explained by abnormal loading conditions (eg, another cardiac or systemic disease) and peak LVOT gradient of ≥ 30 mmHg at rest or with provocation.\n* Has documented LVEF of ≥ 55% recorded by echocardiography within the last 6 months.\n* Symptoms consistent with NYHA functional class II-IV.\n* Receiving beta blocker (BB)s, non-dihydropyridine calcium. channel blockers (nonDHP CCBs), disopyramide, and\u002For mavacamten (once available) as part of routine clinical care; or currently receiving no treatment due to intolerance or failure of prior treatment (eg, BBs, non-DHP CCBs, or disopyramide) for obstructive HCM.\n\nEuropean Sub-study\n\n* Diagnosis of obstructive HCM consistent with the most recent European Society of Cardiology (ESC) and American Heart Association\u002FAmerican College of Cardiology (AHA\u002FACC) guidelines\n* Documented LVEF of ≥55% recorded by TTE\n* Documented symptoms consistent with NYHA functional class II-III at enrollment or within 6 months prior to enrollment (if not available at enrollment).\n* As part of routine clinical care for obstructive HCM: receiving BBs, non-DHP CCBs, disopyramide; initiating mavacamten at enrollment; or currently receiving no treatment due to intolerance or failure of prior treatment (e.g., BBs, non-DHP CCBs, or disopyramide).\n\nExclusion Criteria\n\n* Known phenocopy disease (e.g., Fabry disease, amyloidosis) or LV hypertrophy associated with hypertension.\n* Documentation of any fixed obstruction of the outflow tract such as aortic valve stenosis or replacement.\n* Prior treatment of obstructive HCM with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \\[ASA\\]) within 6 months prior to enrollment; participants with an unsuccessful myectomy or percutaneous ASA performed \\> 6 months prior to enrollment may be enrolled.\n* Naïve to treatment for obstructive HCM (ie, never treated with BBs, nonDHP CCBs, or disopyramide).\n\nUnited States Sub-Study\n\n* Receiving an investigational therapeutic agent for obstructive HCM (eg, myosin-inhibitors other than mavacamten) in an interventional clinical trial at participant enrollment.\n* Previously or currently enrolled in a long-term safety extension study of mavacamten (eg, EXPLORER-HCM \\[ClinicalTrials.gov, NCT03470545\\], MAVA-LTE \\[NCT03723655\\], PIONEER-OLE \\[NCT03496168\\], VALORHCM \\[NCT04349072\\], or MAVERICK \\[NCT03442764\\])\n\nEuropean Sub-study\n\n* Receiving an investigational therapeutic agent or any cardiac myosin inhibitor and\u002For modulators for obstructive HCM at patient enrolment\n* Previously or currently enrolled in other HCM registry studies (e.g., TORCH, REMY, EU-PASS)\n* Previously or currently enrolled in a study of mavacamten (e.g., EXPLORER-HCM \\[ClinicalTrials.gov, NCT03470545\\], MAVA-LTE \\[NCT03723655\\], PIONEER-OLE \\[NCT03496168\\], VALOR-HCM \\[NCT04349072\\], MAVERICK \\[NCT03442764\\], or MEMENTO \\[NCT2264899\\])\n* Previously treated with mavacamten",{"count":264,"type":21},1700,"This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment.\n\nUnited States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.\n\nEurope Sub-Study: The purpose of this study is to evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.",[267],"Obstructive Hypertrophic Cardiomyopathy",[269,270,271,272,273],"Obstructive hypertrophic cardiomyopathy","Obstructive HCM (oHCM)","Mavacamten","Heart failure","oHCM",{"date":70,"type":37},{"date":276,"type":37},"2022-08-16",{"date":278,"type":21},"2029-08-17",{"name":43,"class":44},101,{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":290,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":184},"100617939","phase-1-a-study-to-assess-the-safety-and-tolerability-of-bms-986525-alone-and-in-combination-therapy-in-participants-with-relapsedrefractory-small-cell-lung-cancer-100617939","NCT07325136","A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed\u002FRefractory Small Cell Lung Cancer","A Phase 1\u002F2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed\u002FRefractory Small Cell Lung Cancer","Inclusion Criteria\n\n* Participants must have histologically or cytologically documented relapsed\u002Frefractory small cell lung cancer (R\u002FR-SCLC).\n* Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.\n* In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.\n\nExclusion Criteria\n\n* Participants must not have any untreated CNS metastases.\n* Participants must not have an active, known or suspected autoimmune disease.\n* Participants must not have had a prior organ or tissue allograft.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":289,"type":21},240,[59,291],"PHASE2","The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed\u002FRefractory Small Cell Lung Cancer",[294],"Relapsed\u002FRefractory Small Cell Lung Cancer",[296],"Extensive stage-small cell lung cancer (ES-SCLC)","2026-08-17",{"date":135,"type":37},{"date":300,"type":37},"2026-02-03",{"date":302,"type":21},"2029-04-24",{"name":43,"class":44},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":328},"100615320","phase-1-a-study-to-evaluate-the-safety-and-tolerability-of-pumitamig-alone-or-in-combination-with-ipilimumab-in-participants-with-first-line-advanced-or-unresectable-hepatocellular-carcinoma-hcc-rosetta-hcc-206-100615320","NCT07291076","A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)","ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1\u002F2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)","Inclusion Criteria\n\n* Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC).\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have no prior systemic therapy for advanced\u002F unresectable HCC.\n* Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n\nExclusion Criteria\n\n* Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence.\n* Participants must not have an organ transplant or autoimmune disease.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":312,"type":21},198,[59,291],"The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)",[316],"Hepatocellular Carcinoma (HCC)",[318,319,320,321],"First line HCC","Unresectable HCC","Ipilimumab","Pumitamig",{"date":135,"type":37},{"date":324,"type":37},"2026-03-16",{"date":326,"type":21},"2031-10-14",{"name":43,"class":44},67,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":353},"100589230","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-karxt-for-the-treatment-of-manic-episodes-in-bipolar-i-disorder-balsam-2-100589230","NCT06951711","A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)","Inclusion Criteria:\n\n* Participants must have a primary diagnosis of Bipolar-I disorder established by a comprehensive psychiatric evaluation.\n* Participants must be experiencing an acute episode or relapse of mania or mania with mixed features (≤ 3 weeks).\n* Participants must require hospitalization for the acute exacerbation or relapse of mania.\n* Participants must have all psychotropic medications washed out in no more than 14 days prior to the first dose of the study drug.\n* Participants must have a Young Mania Rating Scale (YMRS) score of ≥ 20 at Screening and at Baseline.\n* Participants must have a Clinical Global Impressions-Bipolar (CGI-BP) ≥ 4 at Screening and at Baseline.\n\nExclusion Criteria:\n\n* Participants must not have any primary Diagnostic and Statistical Manual of Mental Disorders (5th Edition, Text Revision) (DSM-5-TR) disorder, other than BP-I with mania or mania with mixed features within 12 months before screening, including BP-I with depression (for previous 3 months only), BP-II disorder, borderline personality disorder, major depressive disorder, and primary psychotic disorder, with the exception of mild anxiety disorders.\n* Participants must not have a primary diagnosis of BP-I with rapid cycling (≥ 4 distinct mood episodes in one year).\n* Participants must not have a DSM-5-TR diagnosis of moderate to severe substance use disorder (except tobacco use disorder) within the 12 months before screening, or current use as determined by urine toxicology screen or alcohol test.\n* Participants must not be at risk for suicidal behavior at screening or the baseline visit as determined by the Investigator's clinical assessment and the Columbia-Suicide Severity Rating Scale (C-SSRS).\n* Participants must not have cirrhosis, liver cancer, clinically significant liver disease based on the liver function test results.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","65 Years",{"count":338,"type":21},274,[24],"This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features.\n\nThe primary objective of the study is to evaluate the efficacy of KarXT compared to placebo in treating symptoms of mania during a 3-week inpatient period. The duration of the study including screening, the double-blind inpatient treatment period and safety-follow-up is no more than seven weeks.",[342],"Bipolar Disorder Type I With Mania or Mania With Mixed Features",[344,345,346],"Bipolar-I disorder","Mania","Bipolar-I disorder with Mania",{"date":135,"type":37},{"date":349,"type":37},"2025-06-13",{"date":351,"type":21},"2026-11-02",{"name":43,"class":44},85,{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":368,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":379},"100563601","phase-1-a-study-to-evaluate-the-safety-tolerability-drug-levels-and-preliminary-efficacy-of-bms-986507-combinations-in-adult-participants-with-advanced-solid-tumors-100563601","NCT06618287","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","A Phase 1\u002F2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors","Inclusion Criteria\n\n* Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Participants must have a life expectancy of at least 3 months at the time of the first dose.\n* Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed\n* Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC.\n* Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC.\n* Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO\u002FCAP criteria, based on the most recently analyzed biopsy or another pathology specimen.\n* Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent.\n\nExclusion Criteria\n\n* Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.\n* Participants with known mutations in EGFR will be excluded (Group A,B and E).\n* Participants must not have a history of serious recurrent infections.\n* Participants must not have a history of severe heart disease.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":362,"type":21},416,[59,291],"The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.",[366,367],"Lung Cancer","Breast Cancer",[369,370,371,372],"Non-Small Cell Lung Cancer (NSCLC)","Epidermal Growth Factor Receptor mutated (EGFRmt)","Epidermal Growth Factor Receptor wild-type (EGFRwt)","Triple-negative breast cancer (TNBC)",{"date":135,"type":37},{"date":375,"type":37},"2025-02-04",{"date":377,"type":21},"2031-02-26",{"name":43,"class":44},66,{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":400},"100553070","phase-1-a-study-to-evaluate-bms-986470-in-healthy-volunteers-and-participants-with-sickle-cell-disease-100553070","NCT06481306","A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease","A Phase 1\u002F2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470","Inclusion Criteria:\n\nCohort A:\n\n* Healthy male and female (who are not of childbearing potential) participants, as determined by the investigator based on medical history and other determinations. Females not of childbearing potential must have been amenorrhoeic for at least 12 months without an alternative medical cause and have follicle-stimulating hormone (FSH) levels of at least 40 IU\u002FL or have undergone a hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.\n* Body mass index (BMI) of 18.0 to 32.0 kg\u002Fm2, inclusive. BMI = weight (kg)\u002F\\[height (m)\\]2 as measured at screening.\n* No evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory assessments beyond what is consistent with the target population.\n\nCohort B:\n\n* Participants with a documented diagnosis of sickle cell disease (SCD) with genotype HbSS, HbSβ0-thal, or HbSβ+-thal.\n* For Cohort B Part 1 only: Participants with ≥ 4 vaso-occlusive crises (VOCs) within the previous 12 months or ≥ 2 VOCs within the previous 6 months. For Cohort B Part 2 only: Participants with ≥ 2 VOCs and ≤ 15 VOCs within the previous 12 months.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have the following laboratory values:\n\n  i) Hemoglobin ≥ 5.5 and ≤ 12 g\u002FdL (males) or ≥ 5.5 and ≤ 10.6 g\u002FdL (females). ii) Absolute neutrophil count ≥ 1500\u002FμL. iii) Platelet count ≥ 100 × 10\\^3\u002FμL. iv) Absolute reticulocyte count \\> 100 × 10\\^3\u002FμL or \\> 50 × 10\\^3\u002FμL if taking hydroxyurea.\n\nExclusion Criteria:\n\nCohort A:\n\n* Any significant medical condition or any condition that confounds the ability to interpret data from the study.\n* Participant has any condition, including the presence of laboratory abnormalities, that places the participant at unacceptable risk if the participant was to participate in the study.\n* Any major surgery or planned surgery (except GI surgery) within 12 weeks of the first study intervention administration.\n\nCohort B:\n\n* Participants with any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.\n* For Cohort B Part 1 only: participants with more than 6 severe VOCs defined as VOCs requiring ≥ 24 hours of hospital admission within 12 months prior to the first dose of study intervention.\n* For Cohort B Part 1 only: participants with any episode of acute chest syndrome within the last 6 months prior to the first dose of study intervention.\n* Creatinine clearance (CrCl) \\\u003C 60 mL\u002Fmin\u002F1.72m2 using Chronic Kidney Disease Epidemiology (CKD-EPI) equation.\n\nCohort A and B:\n\n* Participant is receiving regularly scheduled RBC or platelet transfusions or has received a RBC transfusion within 28 days and a platelet transfusion within 14 days prior to starting treatment with BMS-986470.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":388,"type":21},224,[59,291],"The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.",[392,393],"Anemia, Sickle Cell","Healthy Volunteers",{"date":135,"type":37},{"date":396,"type":37},"2024-07-17",{"date":398,"type":21},"2027-11-16",{"name":43,"class":44},32,{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":420},"100523047","phase-1-a-study-to-assess-bms-986458-alone-and-in-combination-with-anti-lymphoma-agents-in-relapsedrefractory-non-hodgkin-lymphomas-100523047","NCT06090539","A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed\u002FRefractory Non-Hodgkin Lymphomas","A Phase 1\u002F2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed\u002FRefractory Non-Hodgkin Lymphomas (R\u002FR NHL)","Inclusion Criteria:\n\n* Participants ≥ 18 years of age with frontline or R\u002FR NHL.\n* Participant must have measurable disease (defined by at least one FDG-avid lesion for FDG-avid disease and one bi-dimensionally measurable disease on cross sectional imaging by computed tomography or magnetic resonance imaging with at least one lesion \\> 1.5 cm in the transverse diameter).\n* Participants must accept and follow pregnancy prevention plan.\n\nExclusion Criteria:\n\n* Participants must not have an Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2.\n* Participants with an inability to comply with listed restrictions, precautions and prohibited treatments.\n* Participants must not have prior CAR-T, or radiotherapy ≤ 4 weeks, systemic anticancer treatment ≤ 5 half-lives or 4 weeks, allogeneic SCT ≤ 6 months (only applicable to BMS-986458 single agent or rituximab combination cohorts), or autologous SCT ≤ 3 months prior to study intervention initiation.\n* In BMS-986458 + T-cell engager combination cohorts: Participants must not have prior alloSCT or solid organ transplantation, history of confirmed progressive multifocal leukoencephalopathy (PML); known or suspected history of hemophagocytic lymphohistiocytosis (HLH); known or suspected chronic active Epstein-Barr (EBV) infection.\n* Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.\n* Participants must not have known or suspected central nervous system involvement.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":409,"type":21},460,[59,291],"The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed\u002Frefractory non-Hodgkin Lymphoma.",[413],"Relapsed\u002FRefractory Non-Hodgkin Lymphoma",{"date":135,"type":37},{"date":416,"type":37},"2023-12-29",{"date":418,"type":21},"2028-10-28",{"name":43,"class":44},73,{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":428,"maxAge":54,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":446},"100421767","phase-3-a-study-to-evaluate-the-drug-levels-efficacy-and-safety-of-deucravacitinib-in-children-and-adolescent-participants-with-moderate-to-severe-plaque-psoriasis-100421767","NCT04772079","A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis","Inclusion Criteria\n\n* Males and females aged 12 to \\\u003C18 years for Cohort 1. Males and females aged 4 to \\\u003C12 years for Cohort 2.\n* Plaque psoriasis for at least 6 months.\n* Moderate to severe disease.\n* Candidate for phototherapy or systemic therapy.\n* Must have completed the Week 52 treatment period in Part A or B for long-term extension (LTE) period.\n\nExclusion Criteria\n\n* Participants weighing ≤ 30.0 kg at screening for Cohort 1 (age 12 to \\\u003C 18 years), Part A and Part B. Participants weighing \\\u003C 18.0 kg at screening for Cohort 2 (age 4 to \\\u003C 12 years), Part A and Part B.\n* Other forms of psoriasis.\n* History of recent infection.\n* Prior exposure to deucravacitinib (BMS-986165) or another active comparator.\n* Evidence of active TB for LTE period.\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.","4 Years",{"count":430,"type":21},153,[24],"The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to \\\u003C18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \\\u003C18 years) and Cohort 2 (age 4 to \\\u003C12 years), with two parts; for each cohort. Part A will evaluate the drug levels of BMS-986165 to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose levels in children and adolescent participants with moderate to severe plaque psoriasis. The 5-year long-term extension (LTE) period will observe the long-term safety and tolerability of deucravacitinib in children and adolescent participants with psoriasis who have completed Parts A or B of the study.",[27],[435,247,436,29,437,438,27,439],"Adolescent Psoriasis","Clinical trial","Children Psoriasis","Pediatric Psoriasis","Psoriasis",{"date":135,"type":37},{"date":442,"type":37},"2021-03-23",{"date":444,"type":21},"2033-09-08",{"name":43,"class":44},65,{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":336,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":455,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":475},"100652308","phase-2-a-study-to-evaluate-bms-986511-in-adults-with-major-depressive-disorder-100652308","NCT07772531","A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder","A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of BMS-986511 in Two Sequential Parts in Participants With Major Depressive Disorder","Inclusion Criteria:\n\n* Participants must meet the MDD diagnosis per DSM-5 criteria confirmed by structured interview.\n* Participant must have current moderate to severe MDE confirmed by clinical assessment and validated scale.\n* Participant must have current MDE duration \\>12 weeks at screening.\n* Outpatient participants able to comply with study procedures.\n* Participant require medication washout completed before baseline.\n* Participant must have BMI within protocol range.\n* Participants must meet reproductive safety requirements.\n\nExclusion Criteria:\n\n* Participants must not have other primary psychiatric disorders or a history of treatment-resistant depression during the current episode.\n* Participants must not have recent history of active suicidal ideation or attempt within the past year.\n* Participants must not have prior lifetime treatment with electroconvulsive therapy, ketamine\u002Fesketamine, deep brain stimulation, or transcranial magnetic stimulation.\n* Participants must not have recent history of alcohol\u002Fsubstance abuse or use of cannabis.\n* Participants must not have significant ECG abnormalities, or poorly controlled diabetes.\n* Other protocol defined inclusion\u002Fexclusion criteria apply.",{"count":172,"type":21},[291],"A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder",[458],"Major Depressive Disorder",[458,460,461,462,463,464,465,466,467],"Depression","BMS-986511","Evifacotrep","TRPC4\u002F5 Inhibitor","Antidepressant","Mood Disorders","Central Nervous System","MDD","2026-08-14",{"date":70,"type":37},{"date":471,"type":21},"2026-10-30",{"date":473,"type":21},"2028-11-06",{"name":43,"class":44},26,{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":485,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":497},"100609959","phase-2-a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or-metastatic-colorectal-cancer-100609959","NCT07221357","A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","ROSETTA CRC-203: A Blinded, Randomized Phase 2\u002F3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","Inclusion Criteria\n\n* Participant must previously untreated, histologically confirmed recurrent or metastatic colorectal adenocarcinoma, not amenable to curative surgery.\n* Participant must have no known presence of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) per historical results (a validated test should be used).\n* Participant must have no known presence of the gene that encodes the protein B-Raf (BRAF) V600E mutation per local testing.\n* Participant must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n\nExclusion Criteria\n\n* Participant must not have any untreated known central nervous system (CNS) metastases including brain, leptomeningeal and\u002For spinal cord compression.\n* Participant must not have any prior malignancy active within the previous 2 years, except for locally curable cancers that have been apparently cured and considered to be of low risk of recurrence.\n* Participant must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis or cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, and\u002For ≥ 100 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome.\n* Participant must not have prior systemic treatment with an anti-PD-1, anti-programmed death (ligand)-1 (PD-L1), anti-PD-L2, CD137 agonists, or anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways or chemotherapy.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":484,"type":21},990,[291,24],"The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer",[488],"Untreated, Unresectable, or Metastatic Colorectal Cancer",[490],"Metastatic Colorectal Cancer (mCRC)",{"date":297,"type":37},{"date":493,"type":37},"2025-12-31",{"date":495,"type":21},"2034-03-11",{"name":43,"class":44},283,{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":508,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":521},"100559227","phase-3-a-study-to-compare-the-efficacy-of-nivolumab-and-relatlimab-plus-chemotherapy-vs-pembrolizumab-plus-chemotherapy-for-stage-ivrecurrent-non-squamous-non-small-cell-lung-cancer-with-pd-l1-expression--1-100559227","NCT06561386","A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV\u002FRecurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%","RELATIVITY1093","Inclusion Criteria\n\n* Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.\n* Participants must have measurable PD-L1 ≥ 1% Tumor Cell (TC) score by the investigational PD-L1 immunohistochemistry (IHC) assay VENTANA PD-L1 (SP263) CDx Assay conducted by central laboratory during the screening period prior to randomization.\n* Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria.\n* Participants must have an Easter Cooperative Oncology Group (ECOG) performance status of ≤ 1 at screening.\n* Participants must have a life expectancy of at least 3 months at the time of randomization.\n\nExclusion Criteria\n\n* Participants must not be pregnant and\u002For breastfeeding.\n* Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown EGFR, ALK, or ROS-1 status are excluded.\n* Participants with known BRAFV600E mutations, that are sensitive to available targeted inhibitor therapy; participants with known activating rearranged during transfection (RET) mutations or neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded. Participants with unknown or indeterminate BRAF mutation, activating RET mutations or NTRK fusion gene alterations are eligible.\n* Participants must not have untreated central nervous system (CNS) metastases.\n* Participants must not have leptomeningeal metastases (carcinomatous meningitis).\n* Participants must not have concurrent malignancy requiring treatment.\n* Participants must not have an active autoimmune disease.\n* Participants must not have history of interstitial lung disease or pneumonitis that required oral or intravenous (IV) glucocorticoids to assist with management.\n* Participants must not have a history of myocarditis.\n* Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":507,"type":21},1000,[24],"The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%",[511],"Non-small Cell Lung Cancer",[513,514],"Non-squamous","PDL-1 ≥ 1%",{"date":297,"type":37},{"date":517,"type":37},"2024-10-07",{"date":519,"type":21},"2032-08-04",{"name":43,"class":44},322,{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":22,"phases":531,"briefSummary":532,"conditions":533,"keywords":545,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":254},"100431255","phase-1-a-study-of-bms-986340-as-monotherapy-and-as-combination-therapy-in-participants-with-advanced-solid-tumors-100431255","NCT04895709","A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","A Phase 1\u002F2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","Inclusion Criteria\n\n* Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Radiographically documented progressive disease on or after the most recent therapy.\n* Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced\u002Fmetastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.\n* Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.\n\nExclusion Criteria\n\n* Women who are pregnant or breastfeeding.\n* Primary central nervous system (CNS) malignancy.\n* Untreated CNS metastases.\n* Leptomeningeal metastases.\n* Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment.\n* Active, known, or suspected autoimmune disease.\n* Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment.\n* Prior organ or tissue allograft.\n* Uncontrolled or significant cardiovascular disease.\n* Major surgery within 4 weeks of study drug administration.\n* History of or with active interstitial lung disease or pulmonary fibrosis.\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.",{"count":530,"type":21},1109,[59,291],"The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.",[534,535,536,537,538,539,540,541,542,543,544],"Cervical Cancer","Gastric\u002FGastroesophageal Junction Adenocarcinoma","Microsatellite Stable Colorectal Cancer","Non-Small-Cell Lung Cancer","Squamous Cell Carcinoma of Head and Neck","Carcinoma, Renal Cell","Urothelial Carcinoma","Pancreatic Adenocarcinoma","Melanoma","Ovarian Neoplasms","Triple Negative Breast Neoplasms",[546,534,547,548,549,535,550,536,551,552,537,553,554,538,539,540,541,542,543,544,555,321],"BMS-986340","CRC","First-in-human","GEJ","HNSCC","MSS CRC","Nivolumab","NSCLC","SCCHN","Docetaxel",{"date":297,"type":37},{"date":558,"type":37},"2021-05-27",{"date":560,"type":21},"2031-08-31",{"name":43,"class":44},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":575,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":592},"100626882","phase-3-long-term-extension-study-to-evaluate-safety-and-tolerability-of-admilparant-in-participants-with-pulmonary-fibrosis-100626882","NCT07441408","Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis","An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis","Inclusion Criteria:\n\n\\- Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015.\n\nExclusion Criteria:\n\n* Any disease\u002Fcondition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation.\n* Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015.\n* Exhibit symptoms of heart failure at rest.\n* History of lung reduction surgery or lung transplant.\n* Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":570,"type":21},2380,[24],"The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).",[574],"Pulmonary Fibrosis",[576,577,578,579,580,581,582,583,584],"LPA1 receptor antagonist","Idiopathic pulmonary fibrosis","Progressive pulmonary fibrosis","Long-term extension","IPF","PPF","IM027068","IM0271015","Follow up","2026-08-13",{"date":468,"type":37},{"date":588,"type":21},"2026-12-16",{"date":590,"type":21},"2030-03-30",{"name":43,"class":44},275,{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":114,"enrollmentInfo":600,"targetDuration":4,"studyType":22,"phases":602,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":76},"100597811","phase-1-a-study-to-evaluate-novel-karx-and-kart-prototypes-versus-the-karxt-and-karx-ec-reference-following-single-doses-and-to-explore-the-effect-of-food-after-multiple-doses-of-selected-prototypes-in-healthy-adult-participants-100597811","NCT07063342","A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses","Phase 1, 4-Part, Open-label (Parts 1 to 3) and Double-blind (Part 4) Study to Evaluate the Pharmacokinetics of Novel KarX (BMS-986519) and KarT (BMS-986520) Prototypes Versus the KarXT (BMS-986510) and KarX-EC (BMS-986519) Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants, and to Evaluate Alternative Formulations of KarX (BMS-986519) and KarXT (BMS-986510) Following Single and Multiple Ascending Doses in Healthy Adult Participants","Inclusion Criteria:\n\n* BMI between 18.0 kg\u002Fm2 to 32.0 kg\u002Fm2, inclusive, at screening.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":601,"type":21},236,[59],"The purpose of this study is to evaluate novel KarX and KarT prototypes versus the KarXT and KarX-EC reference following single doses, to explore the effect of food after multiple doses of selected prototypes, and to evaluate alternative formulations of KarX and KarXT following single and multiple ascending doses in healthy adult participants.",[393],{"date":297,"type":37},{"date":607,"type":37},"2025-06-27",{"date":609,"type":21},"2027-03-29",{"name":43,"class":44},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":22,"phases":620,"briefSummary":621,"conditions":622,"keywords":624,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":640},"100565753","phase-3-a-study-to-compare-the-efficacy-and-safety-of-bms-986489-bms-986012-nivolumab-fixed-dose-combination-in-combination-with-carboplatin-plus-etoposide-to-that-of-atezolizumab-with-carboplatin-plus-etoposide-as-first-line-therapy-in-participants-with-extensive-stage-small-cell-lung-cancer-tigos-100565753","NCT06646276","A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","Inclusion Criteria\n\n* Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).\n* Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.\n* Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system\n\nExclusion Criteria\n\n* Participants have already received certain types of treatment for extensive stage small cell lung cancer\n* Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":619,"type":21},530,[24],"The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.",[623],"Extensive-Stage Small Cell Lung Cancer",[625,626,623,627,628,552,629,630,631,632,633],"BMS-986489","BMS-986012","Etoposide","Carboplatin","TIGOS","fucGM1","SCLC","ES-SCLC","atigotatug",{"date":468,"type":37},{"date":636,"type":37},"2025-02-25",{"date":638,"type":21},"2031-09-05",{"name":43,"class":44},183,{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":17,"minAge":648,"maxAge":236,"enrollmentInfo":649,"targetDuration":4,"studyType":22,"phases":651,"briefSummary":652,"conditions":653,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":661},"100615127","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-karxt-for-the-treatment-of-schizophrenia-in-adolescents-emergent-teen-100615127","NCT07288567","A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)","A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)","Inclusion Criteria:\n\n* Diagnosis of schizophrenia as defined by the The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,Text Revision (DSM-5-TR) criteria, confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime version (K-SADS-PL) and experiencing symptoms of psychosis at screening (Visit 1).\n* PANSS total score of at least 70 at screening (Visit 1) and randomization (Visit 2).\n* Participant has a CGI-S score of ≥ 4 at screening (Visit 1) and randomization (Visit 2).\n\nExclusion Criteria:\n\n* Any primary DSM-5-TR disorder other than schizophrenia within 12 months before screening.\n* History or presence of clinically significant cardiovascular, pulmonary, hepatic impairment, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.\n* All grades of hepatic impairment (mild \\[Child-Pugh Class A\\], moderate \\[Child-Pugh Class B\\], and severe \\[Child-Pugh Class C\\]). Participants with known intellectual disability defined as an IQ less than 70; or, either clinical evidence or known social or school history indicative of intellectual disability.\n* Any neurological disorder, except for Tourette's Syndrome.\n* Participants who have either a systolic blood pressure (sBP) or diastolic blood pressure (dBP) meeting criteria for stage 2 HTN, regardless of the presence or absence of symptoms.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","13 Years",{"count":650,"type":21},166,[24],"The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.",[155],"2026-08-12",{"date":585,"type":37},{"date":657,"type":37},"2026-01-29",{"date":659,"type":21},"2029-12-18",{"name":43,"class":44},39,""]